Biological
BCMA CAR-T cells
BCMA CAR-T cells is a biological therapy with 5 clinical trials. Currently 1 active trials ongoing.
Total Trials
5
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
1(20%)
Phase Distribution
Ph phase_1
3
60%
Ph early_phase_1
1
20%
Ph phase_2
1
20%
Phase Distribution
4
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Early Phase 1First-in-human
1(20.0%)
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Other(4)
Detailed Status
unknown4
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Early Phase 11 (20.0%)
Phase 13 (60.0%)
Phase 21 (20.0%)
Trials by Status
unknown480%
recruiting120%
Recent Activity
1 active trials
Showing 5 of 5
recruitingphase_1
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
NCT04271644
unknownphase_1
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
NCT04272151
unknownphase_2
A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma
NCT05712083
unknownphase_1
B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma
NCT05150522
unknownearly_phase_1
BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma
NCT03661554
Clinical Trials (5)
Showing 5 of 5 trials
NCT04271644Phase 1
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
NCT04272151Phase 1
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
NCT05712083Phase 2
A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma
NCT05150522Phase 1
B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma
NCT03661554Early Phase 1
BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5